Tag: Biosense Webster
Cerenovus and Biosense Webster among brands newly incorporated into Johnson &...
Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now...
Advertorial: AFib Symposium 2024: Cutting-edge science and practical sessions offer glimpse...
This advertorial is sponsored by Biosense Webster
Biosense Webster founded the AFib Symposium in 2002. Now in its 22nd year, the annual event combines practical...
HRS 2024: Late-breaking data explore safety and efficacy of Varipulse PFA...
Late-breaking results from the pivotal phase of the admIRE pivotal clinical trial, alongside results from the VIRTUE study—both assessing the Varipulse (Biosense Webster) pulsed...
Biosense Webster submits premarket approval application to US FDA for Varipulse...
Biosense Webster has submitted a premarket approval application (PMA) to the US Food & Drug Administration (FDA) for its Varipulse platform. The submission was...
Biosense Webster supports VIRTUE and POLARIS studies of Varipulse PFA system
Biosense Webster has announced support for two collaborative studies, VIRTUE and POLARIS aiming to better understand the use and workflows with the investigational Varipulse...
Varipulse PFA platform granted approval by Japanese Ministry of Health
Biosense Webster has today announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the Varipulse platform for the treatment of...
Biosnese Webster’s Optrell mapping catheter launches in USA
Biosense Webster has today announced the US launch of the Optrell mapping catheter with Trueref technology powered by the Carto 3 system.
The Optrell mapping...
ADVERTORIAL: Pulsed field ablation: A new frontier in the treatment of...
This article was sponsored by Biosense Webster
According to data published by Patrick M McCarthy (Feinberg School of Medicine, Chicago, USA) and colleagues in the...
Biosense Webster QDot Micro catheter found to improve ablation efficiency for...
Biosense Webster—a stem of Johnson & Johnson MedTech—announced that data from the Q-FFICIENCY study was published in JACC: Clinical Electrophysiology. The study evaluated the...
Heliostar radiofrequency balloon ablation catheter gets European launch
Biosense Webster has announced the European launch of the Heliostar radiofrequency balloon ablation catheter. Heliostar is indicated for use in catheter-based cardiac electrophysiological mapping...
Biosense Webster launches Octaray mapping catheter
Biosense Webster has announced the release of the Octaray mapping catheter, developed for the mapping of cardiac arrhythmias including atrial fibrillation (AF). The catheter...
Pulsed field ablation poised to revolutionise the treatment of atrial fibrillation
The advent of pulsed field ablation (PFA) will revolutionise the treatment of atrial fibrillation (AF), Tom de Potter (Aalst, Belgium) tells Cardiac Rhythm News,...
First-in-human study demonstrates safety and efficacy of QDOT MICRO ablation catheter
Data presented at Heart Rhythm 2019 (8–11 May, San Francisco, USA) and published in JACC: Clinical Electrophysiology indicates that the QDOT MICRO (Biosense Webster),...
First AF patient treated in US IDE study evaluating QDot Micro...
It was recently announced that Biosense Webster has enrolled and treated the first patient in its US Investigational Device Exemption (IDE) study, which evaluates...
First patient treated in STELLAR US study evaluating next-generation balloon ablation...
Biosense Webster has enrolled and treated the first patient in its STELLAR US investigational device exemption (IDE) study. The study will evaluate the safety...
New report on the burden of AF in Europe released
During AF Association Global AF Aware Week, Biosense Webster EMEA has published a report that uncovers the growing burden of atrial fibrillation (AF) on...
Biosense Webster announces first patients enrolled in post-market approval study for...
Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External...
New data demonstrates >90% year 1 success rate for radiofrequency ablation...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...
Biosense Webster launches Carto 3 system Carto Visitag module with Ablation...
Biosense Webster has launched of the Carto Visitag module with Ablation Index, a new technology providing visual indication based on the integration of power,...
Biosense Webster announces US launch of ThermoCool SmartTouch SF catheter
Biosense Webster has announced the US launch of the ThermoCool SmartTouch SF catheter. According to a company release, the catheter pairs contact force technology...